The FDA announced on Sept. 29, 2014, that Baxter Healthcare Corp. voluntarily recalled Dopamine Hydrochloride and 5% Dextrose Injection due to a lack of sterility assurance caused by a potential bag leak. The recall affects 11,808 bags distributed nationwide and in Canada.
How to tell if you have it
- Brand: Baxter
- Product: Dopamine Hydrochloride and 5% Dextrose INJ, USP, 200 mg per 250 mL, Rx Only
- Manufacturer: Baxter USA
- NDC: 0338-1005-02
- Lot#: P303172
- Expiration: 12/14
The hazard
A small cut in the solution bag may have been introduced during manufacturing, resulting in a leak into the overpouch. This defect creates a lack of assurance of sterility for the affected units.
Context
GovInfoNow's records show Baxter Healthcare Corp. has 34 other recalls on record since Sept. 21, 2012. Other recent recalls include the Baxter Amia Dialysis Set recall on Sept. 1, 2017, and the Brevibloc Injection recall due to discoloration on April 12, 2016. Additional similar product recalls by Baxter occurred on Aug. 6, 2026, involving Vasopressin, Famotidine, and Dexmedetomidine Injections for CGMP deviations risk.